The latest financial statement is for the quarter ending 2026-03-28.
| Cash Flow | 2026-03-28 | 2025-12-27 | 2025-09-27 | 2025-06-28 |
|---|---|---|---|---|
| Net income (loss) | -14,802 | -276,290 | 55,556 | 52,693 |
| Depreciation and amortization | 67,151 | 78,277 | 85,164 | 119,507 |
| Goodwill impairment | - | 165,000 | - | - |
| Long-lived asset impairments | 15,863 | 222,895 | 4,982 | 20,627 |
| Stock-based compensation | 22,381 | 17,632 | 23,267 | 17,049 |
| Deferred income taxes | -29,417 | -60,170 | 25,908 | -21,989 |
| Write down of inventories | 1,489 | 1,747 | -370 | 4,305 |
| (gain) loss on venture capital and strategic equity investments, net | - | - | - | -2,525 |
| Losses and impairments on venture capital and strategic equity investments, net | -1,138 | 9,044 | -33,955 | - |
| Provision for credit losses | 47 | 1,503 | 2,368 | 184 |
| (gain) loss on divestitures, net | -117,981 | 0 | 0 | 0 |
| Other, net | 34,675 | 802 | -1,040 | 1,465 |
| Trade receivables and contract assets, net | 65,319 | -27,631 | -26,596 | -10,863 |
| Inventories | -26,004 | 3,497 | 31,327 | -7,929 |
| Accounts payable | 20,455 | -37,878 | 24,506 | -9,010 |
| Accrued compensation | -83,758 | -2,562 | 42,880 | 23,727 |
| Deferred revenue | 5,197 | -25,820 | -23,625 | 12,519 |
| Customer contract deposits | -135 | 15,185 | -1,101 | -8,599 |
| Other assets and liabilities, net | 8,523 | -33,713 | 43,074 | 26,262 |
| Net cash provided by operating activities | 41,077 | 147,520 | 213,826 | 204,603 |
| Acquisition of businesses and assets, net of cash acquired | 405,006 | 0 | 0 | 0 |
| Capital expenditures | 55,908 | 88,950 | 35,580 | 35,298 |
| Purchases of investments and contributions to venture capital investments | 8,492 | 7,532 | 4,454 | 2,788 |
| Proceeds from sale of investments | 2,922 | 3,465 | 3,531 | 504 |
| Proceeds from sale of businesses and assets, net | 60,096 | 0 | 0 | 0 |
| Other, net | 1,457 | -210 | -2,807 | -243 |
| Net cash used in investing activities | -407,845 | -92,807 | -33,696 | -37,339 |
| Proceeds from long-term debt and revolving credit facility | 912,462 | 156,673 | 107,498 | 547,022 |
| Payments on long-term debt, revolving credit facility, and finance lease obligations | 355,676 | 207,817 | 253,794 | 738,312 |
| Proceeds from exercises of stock options | 1,223 | 711 | 2 | 1 |
| Purchase of treasury stock | 208,285 | 96 | 93 | 7,352 |
| Payments of contingent consideration | - | 0 | 0 | 21,822 |
| Purchase of remaining equity interest of other redeemable noncontrolling interests | 0 | 0 | 0 | 0 |
| Other, net | -2,000 | -1,335 | -6,229 | -6,458 |
| Net cash provided by (used in) financing activities | 347,724 | -51,864 | -152,616 | -226,921 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 1,248 | 3,928 | -3,034 | 12,669 |
| Net change in cash, cash equivalents, and restricted cash | -17,796 | 6,777 | 24,480 | -46,988 |
| Cash, cash equivalents, and restricted cash, beginning of period | 215,997 | 209,220 | 184,740 | 231,728 |
| Cash, cash equivalents, and restricted cash, end of period | 198,201 | 215,997 | 209,220 | 184,740 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)